OFOCIR : An Australasian, phase II, multicentre, randomised, dose intensification study investigating oral fludarabine, oral cyclophosphamide and i.v. rituximab (poFCivR) tolerance in previously untreated elderly (= 65 years old) patients with chronic lymphocytic leukaemia (CLL) (Other IDs: ALLG CLL5).

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

65-75Age 65-75

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy,Treatment | Blood / Myeloma / LymphomaChronic Lymphocytic Leukaemia

Trial Overview Read MoreRead more

This phase II trial is assessing two oral drugs and one intravenous drug in previously untreated elderly patients with Chronic Lymphocytic Leukaemia (CLL).
 

This trial is treating patients with Chronic Lymphocytic Leukaemia.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have been diagnosed with cancer, but have not received any treatment.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

An Australasian, phase II, multicentre, randomised, dose intensification study investigating oral fludarabine, oral cyclophosphamide and i.v. rituximab (poFCivR) tolerance in previously untreated elderly (= 65 years old) patients with chronic lymphocytic leukaemia (CLL) (Other IDs: ALLG CLL5).

Cooperative Group

Australasian Leukaemia and Lymphoma Group (ALLG)

Summary

This is a study investigating the tolerance of oral fludarabine, oral cyclophosphamide and i.v. rituximab (poFCivR) in previously untreated elderly (? 65 years old) patients with chronic lymphocytic leukaemia. Patients will be randomly assigned to one of three treatment groups: fludarabine and rituximab alone or fludarabine and rituximab with either 3 or 5 days of oral cyclophosphamide. The primary endpoint will be the proportion of patients completing 6 treatment cycles.

Recruiting Hospitals Read MoreRead more

St Vincent's Hospital, Haematology Oncology Research
Fitzroy
Ms Lisa Demosthenous
lisa.demosthenous@svha.org.au
03 9231 3182

Not Recruiting Hospitals Read MoreRead more

Closed

Frankston Hospital
Frankston
Ms Joan Thomas
JoanThomas@phcn.vic.gov.au
03 9784 8448

Completed

Olivia Newton-John Cancer Wellness & Research Centre
Heidelberg
Ms Samantha Chakar
samantha.chakar@austin.org.au
03 9496 3088

Bendigo Hospital
Bendigo
Ms Amanda Rundle
arundle@bendigohealth.org.au
03 5454 8821

Border Medical Oncology
Albury
Ms Nyree Sarakis
Nsarkis@bordermedonc.com.au
02 6064 1493

Barwon Health, University Hospital Geelong
Geelong
Dr Lea-Anne Harrison
leaanne.harrison@barwonhealth.org.au
03 42 15 2758

Monash Health Haematology Research Unit
Clayton
Ms Anita Cummins
anita.cummins@southernhealth.org.au
03 9594 4044

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Ms Marian Lieschke
marian.lieschke@petermac.org
03 8559 7140

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next